In order to eliminate malaria, it is critical that we have malaria diagnostic tests that are sensitive enough to detect very low levels of infection by any of the five malaria species that infect humans. Malaria infection often does not lead to illness, but symptom-free infected people can transmit parasites to others. ACREME will develop and evaluate new diagnostics tools, including highly sensitive immunosensors and next generation rapid diagnostic tests that can diagnose malaria in the community. People with G6PD deficiency often experience malaria drug toxicity, and we will develop and deploy tests for this condition. Mathematical modelling will be used to determine the impact of new diagnostics on malaria transmission in different settings.